Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | AHR | P35869 | 3/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | CRHBP | P24387 | 1/20 | 0.32 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 2/20 | 0.31 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30664072 | 1.00 | CYP3A4 (0.36) | CYP3A4ALDH1A1GAAAHRHPGD | |
| SCHEMBL1494504 | 0.86 | GAA (0.35) | GAAAHR | |
| SCHEMBL29472174 | 0.80 | ALDH1A1 (0.53) | CYP3A4ALDH1A1AHRHPGDHSD17B10 | |
| SCHEMBL18302718 | 0.79 | GAA (0.32) | GAAAHRKDM1AKDM1B | |
| SCHEMBL20303393 | 0.79 | MAPT (0.37) | ALDH1A1GAAKDM1AKDM1B | |
| SCHEMBL30543313 | 0.79 | GAA (0.32) | GAAAHRKDM1AKDM1B | |
| SCHEMBL29428923 | 0.79 | MAPT (0.37) | ALDH1A1GAAKDM1AKDM1B | |
| Fluoride SCHEMBL28376895 | 0.77 | ALDH1A1 (0.50) | CYP3A4ALDH1A1AHRHPGDHSD17B10 | |
| SCHEMBL23832925 | 0.75 | HPGD (0.37) | CYP3A4ALDH1A1GAAHPGDHSD17B10 | |
| SCHEMBL1494369 | 0.75 | GAA (0.34) | ALDH1A1GAAAHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116925111-A | Organic compound and application thereof | 北京鼎材科技有限公司 | 2023-10-24 | — | — | CN | disclosed |
| US-20230157170-A1 | HETEROAROMATIC COMPOUNDS FOR ORGANIC ELECTROLUMINESCENT DEVICES | UDC IRELAND LIMITED (IE) | 2023-05-18 | — | — | US | disclosed |
| US-20230157170-A1 | HETEROAROMATIC COMPOUNDS FOR ORGANIC ELECTROLUMINESCENT DEVICES | UDC IRELAND LIMITED (IE) | 2023-05-18 | — | — | US | disclosed |
| US-20230147279-A1 | HETEROCYCLIC COMPOUNDS FOR ORGANIC ELECTROLUMINESCENT DEVICES | UDC IRELAND LIMITED (IE) | 2023-05-11 | — | — | US | disclosed |
| US-20230147279-A1 | HETEROCYCLIC COMPOUNDS FOR ORGANIC ELECTROLUMINESCENT DEVICES | UDC IRELAND LIMITED (IE) | 2023-05-11 | — | — | US | disclosed |
| US-20230104248-A1 | POLYCYCLIC COMPOUNDS FOR ORGANIC ELECTROLUMINESCENT DEVICES | UDC IRELAND LIMITED (IE) | 2023-04-06 | — | — | US | disclosed |
| WO-2021185829-A1 | HETEROCYCLIC COMPOUNDS FOR ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2021-09-23 | — | — | WO | disclosed |
| WO-2021185712-A1 | HETEROAROMATIC COMPOUNDS FOR ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2021-09-23 | — | — | WO | disclosed |
| WO-2021122740-A1 | POLYCYCLIC COMPOUNDS FOR ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2021-06-24 | — | — | WO | disclosed |
| US-10844076-B2 | Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine | NEKTAR THERAPEUTICS (US) | 2020-11-24 | — | — | US | disclosed |
| US-20140256732-A1 | OLIGOMER-CONTAINING SUBSTITUTED AROMATIC TRIAZINE COMPOUNDS | NEKTAR THERAPEUTICS (US) | 2014-09-11 | — | — | US | disclosed |
| US-8772479-B2 | Oligomer-containing substituted aromatic triazine compounds | NEKTAR THERAPEUTICS (US) | 2014-07-08 | — | — | US | disclosed |
| US-8772479-B2 | Oligomer-containing substituted aromatic triazine compounds | NEKTAR THERAPEUTICS (US) | 2014-07-08 | — | — | US | disclosed |
| US-8772479-B2 | Oligomer-containing substituted aromatic triazine compounds | NEKTAR THERAPEUTICS (US) | 2014-07-08 | — | — | US | disclosed |
| US-20120122871-A1 | Oligomer-Containing Substituted Aromatic Triazine Compounds | NEKTAR THERAPEUTICS (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122871-A1 | Oligomer-Containing Substituted Aromatic Triazine Compounds | NEKTAR THERAPEUTICS (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122871-A1 | Oligomer-Containing Substituted Aromatic Triazine Compounds | NEKTAR THERAPEUTICS (US) | 2012-05-17 | — | — | US | disclosed |
| EP-2430003-A1 | OLIGOMER-CONTAINING SUBSTITUTED AROMATIC TRIAZINE COMPOUNDS | Nektar Therapeutics (US) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010132691-A1 | OLIGOMER-CONTAINING SUBSTITUTED AROMATIC TRIAZINE COMPOUNDS | NEKTAR THERAPEUTICS (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132691-A1 | OLIGOMER-CONTAINING SUBSTITUTED AROMATIC TRIAZINE COMPOUNDS | NEKTAR THERAPEUTICS (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230104248-A1 | POLYCYCLIC COMPOUNDS FOR ORGANIC ELECTROLUMINESCENT DEVICES | VDAC2, VDAC3, KCNC1 | CYP3A4 1052/4885ALDH1A1 1101/4885GAA 3035/4885 |
| US-10844076-B2 | Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine | KCNJ2, TRPC5, RYR2 | CYP3A4 829/4885ALDH1A1 1704/4885GAA 2406/4885 |
| US-20120122871-A1 | Oligomer-Containing Substituted Aromatic Triazine Compounds | NOD2, HTT, CUL5 | CYP3A4 359/4885ALDH1A1 3391/4885GAA 1674/4885 |
| US-20140256732-A1 | OLIGOMER-CONTAINING SUBSTITUTED AROMATIC TRIAZINE COMPOUNDS | NOD2, HTT, IPO5 | CYP3A4 625/4885ALDH1A1 2630/4885GAA 712/4885 |
| US-20230147279-A1 | HETEROCYCLIC COMPOUNDS FOR ORGANIC ELECTROLUMINESCENT DEVICES | DDT, VDAC2, KCNC1 | CYP3A4 307/4885ALDH1A1 649/4885GAA 2667/4885 |
| US-20230157170-A1 | HETEROAROMATIC COMPOUNDS FOR ORGANIC ELECTROLUMINESCENT DEVICES | DDT, CTCF, EED | CYP3A4 185/4885ALDH1A1 628/4885GAA 2805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.